Herceptin Injections Equal More Convenience and Less Cost

TON - Daily

Results from a phase 3 study of women with HER2-positive early breast cancer showed that administering Herceptin (trastuzumab) by subcutaneous (SC) injection leads to efficacy comparable to the current intravenous (IV) Herceptin treatment. Due to its less invasive administration and quicker administration time (5 minutes vs 30-90 minutes), Herceptin SC may allow greater convenience for patients versus the traditional IV method. This is important in the early breast cancer setting, as Herceptin is usually prescribed for 1 year.

“The subcutaneous formulation of Herceptin provides an alternative to intravenous Herceptin and is an important treatment option for patients with HER2 positive breast cancer,” said Hal Barron, MD, Chief Medical Officer and Head, Global Product Development. “Because it is less invasive and takes 5 rather than 30-90 minutes to administer, subcutaneous Herceptin is more convenient for patients and may reduce healthcare costs relative to the standard intravenous formulation.”

The phase 3, randomized, open-label, international, multicenter study, titled HannaH, involved a total of 596 patients with operable or locally advanced early breast cancer. The study investigated the efficacy, pharmacokinetics and safety of Herceptin SC and Herceptin IV in the neoadjuvant–adjuvant treatment setting of women with HER2-positive early breast cancer. Treatment duration was 1 year in total for both arms.

Participants in the Herceptin SC arm received:

  • 600 mg (fixed dose) of Herceptin SC plus chemotherapy for 8 cycles before surgery
  • Herceptin SC alone for 10 cycles after surgery

Participants in the Herceptin IV arm received:

  • An initial 8 mg/kg body weight loading dose of Herceptin IV followed by 6 mg/kg maintenance dose, both in combination with chemotherapy, for a total of 8 cycles before surgery, as per the standard IV regimen
  • Herceptin IV alone for 10 cycles after surgery

Between arms, all-grade adverse events (AEs) and severe AEs were comparable. The most frequent AEs (>25%) in either arm were alopecia, nausea, neutropenia, diarrhea, asthenia, and fatigue.

Source: Roche.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: